TrialInternational journal of rheumatic diseases2020

A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.

Hideto Kameda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.